Trials / Active Not Recruiting
Active Not RecruitingNCT05120830
NTLA-2002 in Adults With Hereditary Angioedema (HAE)
Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults With Hereditary Angioedema (HAE)
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Intellia Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Biological NTLA-2002 | CRISPR/Cas9 gene editing system delivered by LNP for IV administration |
| OTHER | Normal Saline IV Administration | The administration of IV normal saline |
Timeline
- Start date
- 2021-12-10
- Primary completion
- 2024-04-04
- Completion
- 2026-07-01
- First posted
- 2021-11-15
- Last updated
- 2026-03-24
Locations
9 sites across 6 countries: Australia, France, Germany, Netherlands, New Zealand, United Kingdom
Source: ClinicalTrials.gov record NCT05120830. Inclusion in this directory is not an endorsement.